. Radioactivity recovered in bile, urine and gastric contents of rats receiving
ascorbic acid 2-[3sS]sulphate derivative either intraduodenally or intravenously
For details see the text. Results are expressed as percentage of administered radioactivity. The results for the intraduodenal administration are means for four animals. with the ranges in parentheses, animals.
35S in gastric contents
Total 3sS in urine jSS in bile and those for intravenous administration are means for two Time (h) 0-1 1-2 2-3 3-4
4-5
0-5
0-5 0-5
Intraduodenal administration 7.1 (6.2-8.4) 6.5 (4.3-8.2) 7.3 (5.7-9.6) 6.2 (5.9-7.5) 7.5 (7.0-8.9) In preliminary studies the 35S-labelled derivative (0.24ml) was administered either intravenously or intraduodenally to wholly anaesthetized rats. The radioactivity recovered over 5 h was low, up to 1.2 % (of the dose) in urine and up to 5.4% in bile.
Similarly, in experiments with free-range rats receiving the derivative intravenously only 15-24% of the adminstered 35S was excreted in the urine over 5 days.
The 35S retained by the animal was located by whole-body radioautography (Powell et al., 1967) . Young male rats (approx. 50g body wt.) each received the derivative (0.24ml) intravenously and were killed at intervals ranging from 2 h to 24 h after injection. Radioautograms subsequently prepared were unusual in that they demonstrated that the radioactivity was almost exclusively associated with the gastric mucosa, gastric contents and intestinal contents.
In further experiments, the rate and extent of secretion of radioactivity into the gastric lumen was investigated in anaesthetized rats. Male rats with stomach, ureter and bileduct cannulae received the 35S-labelled derivative (0.241111) intraduodenally. Gastric contents were collected by lavage at hourly intervals over 5 h, and bile and urine were collected as single fractions over 5 h. In contrast with the low recovery in urine and bile, significant amounts of radioactivity were secreted into the gastric lumen. Between 4.3 and 9.6% (of the injected radioactive dose) was secreted every hour of the experimental period, and over 5h up to 36% of the dose was recovered from the stomach. Similar values were obtained when the derivative was administered intravenously (see Table 1 ). Analysis of the gastric contents by t.1.c. in three solvents showed that a single 35S-labelled substance identical in mobility with the administered compound was secreted into the stomach.
The results summarized in Table 1 demonstrated that the rate of transfer of 35S into the stomach is remarkably constant. However, the possibility existed that the rate of secretion of 35S was enhanced by gastric lavage. Therefore the 35S-labelled derivative was administered intraduodenally and the gastric contents were removed as a single sample after 5 h. Of the administered radioactivity, approx. 55 % was recovered from the stomach, demonstrating that secretion into the gastric lumen is a major route in the distribution of the 35S-labelled derivative in the intact animal. Intravenously administered histamine (175pg/rat) had no effect on the amount of 35S secreted into the gastric lumen. The experiments demonstrating the enterogastric circulation in the rat were repeated with the guinea pigs and substantially the same results were obtained.
Collectively, these results show that the distribution of the ascorbic acid 2-rJ5S]-sulphate derivative in viuo is determined largely by an enterogastric circulation of the unchanged material. The chemical nature of the labelled derivative has not been fully elucidated, although it is clearly not inorganic [35S]sulphate.
The significance of the work reported here is twofold: firstly in relation to ascorbic acid 2-sulphate and secondly in relation to the demonstrated enterogastric circulation.
Predictably, attention has been directed to the possible role of ascorbic acid 2-sulphate in the mode of action of the vitamin itself, but it is not clear whether the sulphate represents an inactive metabolite or an active biological intermediate. Ford & Ruoff (1965) postulated a sulphating role in vivo, and subsequent isolation of the ester from a number of sources, for example brine shrimps (Mead & Finamore, 1969) , fish (Baker et al., 1971 (Baker et al., , 1973 , rat organs Baker et af., 1973) and human urine (Baker et al., 1971) (Shapiro & Poon, 1975) . The role of ascorbic acid 2-sulphate in the sulphation of cholesterol is also unclear (Verlangieri & Mumma, 1973) . Other investigations on the anti-scorbutic properties of the sulphate ester of ascorbic acid have yielded conflictingresults (Mummaetal., 1972; Campeauetal., 1973) . Althoughitis notclaimedthat the work reported here clarifies the role of ascorbic acid sulphate, it may well explain some of the anomalous results obtained by other workers using the 35S-labelled ester. In particular, the work of Hornig (1974) on the metabolic fate of the 35S-labelled ester sulphate in rats and guinea pigs, showing the variations in the extents of secretion and recovery of radioactivity could be rationalized if the 35S-labelled preparation could not be identified with pure L-ascorbic acid 2-[35S]sulphate.
It is not suggested that the enterogastric circulation exists for the circulation of the ascorbic acid 2-[3sS]sulphate derivative, but that this compound is utilizing a conservation route normally travelled by naturally occurring compounds. It seems likely that this circulatory route may be a n important mechanism of conservation for certain biochemicals and might be exploited for the treatment of gastrointestinal disorders.
